サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1462973

脊椎バイオロジクス市場、シェア、規模、動向、産業分析レポート：製品別、エンドユーザー別、地域別、セグメント別予測、2024-2032年

Spine Biologics Market Share, Size, Trends, Industry Analysis Report, By Product (Bone Graft Substitutes, Spinal Allografts, Others); By End User; By Region; Segment Forecast, 2024- 2032

出版日
ページ情報
英文 116 Pages
納期
即日から翌営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
脊椎バイオロジクス市場、シェア、規模、動向、産業分析レポート：製品別、エンドユーザー別、地域別、セグメント別予測、2024-2032年
出版日: 2024年03月24日
発行: Polaris Market Research
ページ情報: 英文 116 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Polaris Market Research社の最新調査によると、脊椎バイオロジクスの世界市場規模は2032年までに31億6,000万米ドルに達する見込みです。この調査レポートは、現在の市場力学を詳細に洞察し、将来の市場成長に関する分析を提供しています。

脊椎バイオロジクス市場は、世界のヘルスケア支出の増加によって牽引されています。変性椎間板症や脊椎骨折のような脊椎疾患の治療により多くの資源が割り当てられる中、脊椎バイオロジクスのような革新的な治療法に対する需要が高まっています。ヘルスケア支出の増加は研究への投資を増やし、骨移植代替物や幹細胞治療といった脊椎用途に合わせた高度な生物学的製剤の開発につながります。さらに、支出の増加はMRIやCTスキャンなどの診断技術へのアクセス強化を支援し、早期発見と治療を促進します。低侵襲手術技術の採用と脊椎バイオロジクスの併用は、患者に従来の手術に代わるより低侵襲な選択肢を提供し、コスト削減に貢献すると同時に市場の成長を促進します。

脊椎バイオロジクス市場は、変性椎間板疾患や脊椎骨折に対して一般的に行われる脊椎固定術への応用拡大によっても成長しています。生物学的製剤は骨の成長を促進し、脊椎の安定性を高めて固定術を成功に導く。バイオテクノロジーの進歩により、革新的な脊椎バイオロジクスが開発され、複雑な脊椎疾患に対するソリューションが提供されています。これらの製品は骨の再生を促し、患者の転帰を改善し、追加介入の必要性を減らします。人口の高齢化と変性脊椎疾患の有病率の増加に伴い、脊椎バイオロジクスに対する需要が高まっています。外科医は、より良い治療結果を求める患者の期待に応えるため、生物学的製剤を治療プロトコールに組み込んでいます。脊椎用途での生物学的治療に対する規制上の承認が市場拡大をさらに後押しし、脊椎バイオロジクス市場の成長を促進しています。

個別化医療は、遺伝的体質、ライフスタイル、疾患の特徴に基づいて治療を調整するアプローチです。高度な遺伝子検査とバイオマーカー分析により、臨床医は各患者に最も適した生物学的製剤を選択し、有効性を最適化し、副作用を最小限に抑えることができます。さらに、個別化医療は、遺伝子治療や精密標的生物学的製剤など、特定の患者サブグループにカスタマイズされた新規生物学的製剤の開発を促進します。ヘルスケアプロバイダー、研究者、バイオテクノロジー企業間のこのような共同作業は、脊椎バイオロジクスの技術革新を促進し、より効果的で患者中心の治療を提供します。

新興国市場は、急速な経済成長とヘルスケア・インフラの整備により、脊椎バイオロジクス市場にチャンスをもたらしています。アジア太平洋、ラテンアメリカ、中東などの地域では、高齢化と都市化による脊椎疾患の有病率の増加に伴い、先進医療に対する需要が高まっています。ヘルスケア支出の増加は、脊椎バイオロジクスを含む革新的技術への投資を可能にします。多国籍企業と現地のヘルスケアプロバイダーとの連携により、製品のイントロダクションと導入が促進されます。このようなパートナーシップは、新興国市場の進化するヘルスケアニーズに対応するための知識交換と市場開拓を促進します。

脊椎バイオロジクス市場レポートハイライト

2023年、脊椎同種移植片分野は、臨床的に受け入れられ、有効性が実証され、疾患伝播リスクが最小であることから、大きな売上シェアを占めました。

2023年には、包括的なケアサービス、高度なインフラ、経験豊富なヘルスケア専門家により、病院・クリニック分野が大きな売上シェアを占めました。

2023年には、北米地域が、高度なヘルスケアインフラ、脊椎疾患の高い有病率、確立された規制枠組みにより、大きな市場シェアを占めました。

同市場は、Arthrex, Inc.、Johnson &Johnson、Medtronic plc、NuVasive, Inc.、Organogenesis Inc.、Orthofix Medical Inc.、Stryker Corporation、Zimmer Biomet Holdings, Inc.など、世界的に存在感を示す市場競合企業が存在するため、競争が激くなっています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 調査手法

第4章 世界の脊椎バイオロジクス市場の洞察

  • 脊椎バイオロジクス市場- 業界スナップショット
  • 脊椎バイオロジクス市場力学
    • 促進要因と機会
      • 脊椎疾患の発生率増加により、製品の需要が増加すると予測される。
      • 低侵襲手術への関心の高まりが脊椎バイオロジクス市場の成長を牽引すると予想される
    • 抑制要因と課題
      • 治療費の高騰が市場の成長を阻害する可能性がある
  • PESTLE分析
  • 脊椎バイオロジクス業界の動向
  • バリューチェーン分析
  • COVID-19の影響分析

第5章 製品別の世界市場

  • 主な調査結果
  • イントロダクション
  • 骨移植代替品
  • 脊椎同種移植
  • その他

第6章 エンドユーザー別の世界市場

  • 主な調査結果
  • イントロダクション
  • 病院と診療所
  • 外来手術センター
  • その他

第7章 地域別の世界市場

  • 主な調査結果
  • イントロダクション
    • 脊椎バイオロジクス市場の評価、地域、2019-2032年
  • 脊椎バイオロジクス市場-北米
    • 北米：脊椎バイオロジクス市場、エンドユーザー別、2019年～2032年
    • 北米：脊椎バイオロジクス市場、製品別、2019年～2032年
    • 脊椎バイオロジクス市場-米国
    • 脊椎バイオロジクス市場- カナダ
  • 脊椎バイオロジクス市場- 欧州
    • 欧州：脊椎バイオロジクス市場、エンドユーザー別、2019年～2032年
    • 欧州：脊椎バイオロジクス市場、製品別、2019年～2032年
    • 脊椎バイオロジクス市場- 英国
    • 脊椎バイオロジクス市場- フランス
    • 脊椎バイオロジクス市場- ドイツ
    • 脊椎バイオロジクス市場- イタリア
    • 脊椎バイオロジクス市場- スペイン
    • 脊椎バイオロジクス市場- オランダ
    • 脊椎バイオロジクス市場- ロシア
  • 脊椎バイオロジクス市場- アジア太平洋地域
    • アジア太平洋地域：脊椎バイオロジクス市場、エンドユーザー別、2019-2032年
    • アジア太平洋地域：脊椎バイオロジクス市場、製品別、2019年～2032年
    • 脊椎バイオロジクス市場- 中国
    • 脊椎バイオロジクス市場- インド
    • 脊椎バイオロジクス市場- マレーシア
    • 脊椎バイオロジクス市場- 日本
    • 脊椎バイオロジクス市場- インドネシア
    • 脊椎バイオロジクス市場- 韓国
  • 脊椎バイオロジクス市場-中東およびアフリカ
    • 中東およびアフリカ：脊椎バイオロジクス市場、エンドユーザー別、2019-2032年
    • 中東およびアフリカ：脊椎バイオロジクス市場、製品別、2019-2032年
    • 脊椎バイオロジクス市場- サウジアラビア
    • 脊椎バイオロジクス市場-UAE
    • 脊椎バイオロジクス市場- イスラエル
    • 脊椎バイオロジクス市場- 南アフリカ
  • 脊椎バイオロジクス市場-ラテンアメリカ
    • ラテンアメリカ：脊椎バイオロジクス市場、エンドユーザー別、2019年～2032年
    • ラテンアメリカ：脊椎バイオロジクス市場、製品別、2019年～2032年
    • 脊椎バイオロジクス市場- メキシコ
    • 脊椎バイオロジクス市場- ブラジル
    • 脊椎バイオロジクス市場- アルゼンチン

第8章 競合情勢

  • 拡大と買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/契約/公開

第9章 企業プロファイル

  • Arthrex, Inc
  • Baxter International Inc.
  • Exactech, Inc.
  • Globus Medical Inc.
  • Johnson & Johnson（DePuy Synthes）
  • Kuros Biosciences
  • Medtronic plc
  • NuVasive, Inc.
  • Organogenesis Inc.
  • Orthofix Medical Inc.
  • RTI Surgical Holdings, Inc.
  • SeaSpine Holdings Corporation
  • Spine Wave, Inc.
  • Stryker Corporation
  • Zimmer Biomet Holdings, Inc.
図表

List of Tables

  • Table 1 Global Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 2 Global Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 3 Spine Biologics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 4 North America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 5 North America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 6 U.S.: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 7 U.S.: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 8 Canada: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 9 Canada: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 10 Europe: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 11 Europe: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 12 UK: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 13 UK: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 14 France: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 15 France: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 16 Germany: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 17 Germany: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 18 Italy: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 19 Italy: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 20 Spain: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 21 Spain: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 22 Netherlands: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 23 Netherlands: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 24 Russia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 25 Russia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 26 Asia Pacific: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 27 Asia Pacific: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 28 China: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 29 China: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 30 India: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 31 India: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 32 Malaysia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 33 Malaysia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 34 Japan: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 35 Japan: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 36 Indonesia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 37 Indonesia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 38 South Korea: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 39 South Korea: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 40 Middle East & Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 41 Middle East & Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 42 Saudi Arabia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 43 Saudi Arabia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 44 UAE: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 45 UAE: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 46 Israel: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 47 Israel: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 48 South Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 49 South Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 50 Latin America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 51 Latin America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 52 Mexico: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 53 Mexico: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 54 Brazil: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 55 Brazil: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • Table 56 Argentina: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • Table 57 Argentina: Spine Biologics Market, by Product, 2019-2032 (USD Billion)

List of Figures

  • Figure 1 Global Spine Biologics Market, 2019-2032 (USD Billion)
  • Figure 2 Integrated Ecosystem
  • Figure 3 Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4 Market by Geography
  • Figure 5 Porter's Five Forces
  • Figure 6 Market by End User
  • Figure 7 Global Spine Biologics Market, by End User, 2022 & 2032 (USD Billion)
  • Figure 8 Market by Product
  • Figure 9 Global Spine Biologics Market, by Product, 2022 & 2032 (USD Billion)
  • Figure 10 Spine Biologics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 11 Strategic Analysis - Spine Biologics Market
目次
Product Code: PM4665

The global spine biologics market size is expected to reach USD 3.16 billion by 2032, according to a new study by Polaris Market Research. The report "Spine Biologics Market Share, Size, Trends, Industry Analysis Report, By Product (Bone Graft Substitutes, Spinal Allografts, Others); By End User; By Region; Segment Forecast, 2024- 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The spine biologics market is driven by increasing global healthcare expenditure. With more resources allocated to treating spinal disorders like degenerative disc disease and spinal fractures, demand for innovative treatments such as spine biologics is rising. Higher healthcare spending enables greater investment in research, leading to advanced biologic products tailored for spinal applications like bone graft substitutes and stem cell therapies. Additionally, increased expenditure supports enhanced access to diagnostic technologies like MRI and CT scans, facilitating early detection and treatment. Adoption of minimally invasive surgical techniques, coupled with spine biologics, offers patients less invasive alternatives to traditional surgeries, driving market growth while contributing to cost savings.

The spine biologics market is also growing due to expanding applications in spine fusion procedures, commonly performed for degenerative disc disease and spinal fractures. Biologic products promote bone growth and enhance spinal stability, facilitating successful fusion. Advancements in biotechnology have led to innovative spine biologics, offering solutions for complex spinal conditions. These products stimulate bone regeneration, improving patient outcomes and reducing the need for additional interventions. With an aging population and increasing prevalence of degenerative spine conditions, demand for spine biologics is rising. Surgeons are integrating biologic products into treatment protocols to meet patient expectations for better outcomes. Regulatory approvals for biologic treatments in spinal applications further support market expansion, driving growth in the spine biologics market.

Personalized medicine approaches tailor treatments based on genetic makeup, lifestyle, and disease characteristics. Advanced genetic testing and biomarker analysis enable clinicians to select the most suitable biologic therapies for each patient, optimizing efficacy and minimizing side effects. Additionally, personalized medicine fosters the development of novel biologic treatments, including gene therapies and precision-targeted biologics, customized to specific patient subgroups. This collaborative effort between healthcare providers, researchers, and biotech firms drives innovation in spine biologics, offering more effective and patient-centric treatments.

Emerging markets are fostering opportunities in the spine biologics market owing to rapid economic growth and healthcare infrastructure development. In regions like Asia-Pacific, Latin America, and the Middle East, rising demand for advanced medical treatments accompanies the increasing prevalence of spinal disorders due to aging populations and urbanization. Heightened healthcare expenditure enables investment in innovative technologies, including spine biologics. Collaborations between multinational corporations and local healthcare providers facilitate product introduction and adoption. These partnerships drive knowledge exchange and localized development to meet the evolving healthcare needs of emerging markets.

Spine Biologics Market Report Highlights

In 2023, the spinal allografts segment held a significant revenue share owing to clinical acceptance, proven efficacy, and minimal disease transmission risk.

In 2023, the hospitals and clinics segment held a significant revenue share owing to comprehensive care services, advanced infrastructure, and experienced healthcare professionals.

In 2023, the North America region accounted for a significant market share due to advanced healthcare infrastructure, high prevalence of spinal disorders, and well-established regulatory framework.

The market is highly competitive owing to the existence of market players with a global presence, including Arthrex, Inc., Johnson & Johnson, Medtronic plc, NuVasive, Inc., Organogenesis Inc., Orthofix Medical Inc., Stryker Corporation, and Zimmer Biomet Holdings, Inc. among others.

Polaris Market Research has segmented the Spine Biologics market report based on product, end user, and region:

Spine Biologics, Product Outlook (Revenue - USD Billion, 2019 - 2032)

  • Bone Graft Substitutes
  • Spinal Allografts
  • Others

Spine Biologics, End User Channel Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals and Clinics
  • Ambulatory Surgical Centers
  • Others

Spine Biologics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • France
  • Germany
  • UK
  • Italy
  • Netherlands
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
  • Japan
  • China
  • India
  • Malaysia
  • Indonesia
  • South Korea
  • Australia
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Spine Biologics Market Insights

  • 4.1. Spine Biologics Market - Industry Snapshot
  • 4.2. Spine Biologics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing incidence of spinal disorders is projected to spur the product demand
      • 4.2.1.2. Growing preference for minimally invasive procedures is expected to drive spine biologics market growth
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High cost of treatment is likely to impede the market growth
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Spine Biologics Industry trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Spine Biologics Market, by Product

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Spine Biologics, by Product, 2019-2032 (USD Billion)
  • 5.3. Bone Graft Substitutes
    • 5.3.1. Global Spine Biologics Market, by Bone Graft Substitutes, by Region, 2019-2032 (USD Billion)
  • 5.4. Spinal Allografts
    • 5.4.1. Global Spine Biologics Market, by Spinal Allografts, by Region, 2019-2032 (USD Billion)
  • 5.5. Others
    • 5.5.1. Global Spine Biologics Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Spine Biologics Market, by End User

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Spine Biologics Market, by End User, 2019-2032 (USD Billion)
  • 6.3. Hospitals and Clinics
    • 6.3.1. Global Spine Biologics Market, by Hospitals and Clinics, by Region, 2019-2032 (USD Billion)
  • 6.4. Ambulatory Surgical Centers
    • 6.4.1. Global Spine Biologics Market, by Ambulatory Surgical Centers, by Region, 2019-2032 (USD Billion)
  • 6.5. Others
    • 6.5.1. Global Spine Biologics Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Spine Biologics Market, by Geography

  • 7.1. Key findings
  • 7.2. Introduction
    • 7.2.1. Spine Biologics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 7.3. Spine Biologics Market - North America
    • 7.3.1. North America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.3.2. North America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.3. Spine Biologics Market - U.S.
      • 7.3.3.1. U.S.: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.3.3.2. U.S.: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.3.4. Spine Biologics Market - Canada
      • 7.3.4.1. Canada: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.3.4.2. Canada: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.4. Spine Biologics Market - Europe
    • 7.4.1. Europe: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.4.2. Europe: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.3. Spine Biologics Market - UK
      • 7.4.3.1. UK: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.3.2. UK: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.4. Spine Biologics Market - France
      • 7.4.4.1. France: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.4.2. France: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.5. Spine Biologics Market - Germany
      • 7.4.5.1. Germany: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.5.2. Germany: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.6. Spine Biologics Market - Italy
      • 7.4.6.1. Italy: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.6.2. Italy: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.7. Spine Biologics Market - Spain
      • 7.4.7.1. Spain: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.7.2. Spain: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.8. Spine Biologics Market - Netherlands
      • 7.4.8.1. Netherlands: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.8.2. Netherlands: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.4.9. Spine Biologics Market - Russia
      • 7.4.9.1. Russia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.4.9.2. Russia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.5. Spine Biologics Market - Asia Pacific
    • 7.5.1. Asia Pacific: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.5.2. Asia Pacific: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.3. Spine Biologics Market - China
      • 7.5.3.1. China: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.3.2. China: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.4. Spine Biologics Market - India
      • 7.5.4.1. India: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.4.2. India: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.5. Spine Biologics Market - Malaysia
      • 7.5.5.1. Malaysia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.5.2. Malaysia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.6. Spine Biologics Market - Japan
      • 7.5.6.1. Japan: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.6.2. Japan: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.7. Spine Biologics Market - Indonesia
      • 7.5.7.1. Indonesia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.7.2. Indonesia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.5.8. Spine Biologics Market - South Korea
      • 7.5.8.1. South Korea: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.5.8.2. South Korea: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.6. Spine Biologics Market - Middle East & Africa
    • 7.6.1. Middle East & Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.6.2. Middle East & Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.3. Spine Biologics Market - Saudi Arabia
      • 7.6.3.1. Saudi Arabia: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.3.2. Saudi Arabia: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.4. Spine Biologics Market - UAE
      • 7.6.4.1. UAE: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.4.2. UAE: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.5. Spine Biologics Market - Israel
      • 7.6.5.1. Israel: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.5.2. Israel: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.6.6. Spine Biologics Market - South Africa
      • 7.6.6.1. South Africa: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.6.6.2. South Africa: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
  • 7.7. Spine Biologics Market - Latin America
    • 7.7.1. Latin America: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
    • 7.7.2. Latin America: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.3. Spine Biologics Market - Mexico
      • 7.7.3.1. Mexico: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.7.3.2. Mexico: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.4. Spine Biologics Market - Brazil
      • 7.7.4.1. Brazil: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.7.4.2. Brazil: Spine Biologics Market, by Product, 2019-2032 (USD Billion)
    • 7.7.5. Spine Biologics Market - Argentina
      • 7.7.5.1. Argentina: Spine Biologics Market, by End User, 2019-2032 (USD Billion)
      • 7.7.5.2. Argentina: Spine Biologics Market, by Product, 2019-2032 (USD Billion)

8. Competitive Landscape

  • 8.1. Expansion and Acquisition Analysis
    • 8.1.1. Expansion
    • 8.1.2. Acquisitions
  • 8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

  • 9.1. Arthrex, Inc
    • 9.1.1. Company Overview
    • 9.1.2. Financial Performance
    • 9.1.3. Product Benchmarking
    • 9.1.4. Recent Development
  • 9.2. Baxter International Inc.
    • 9.2.1. Company Overview
    • 9.2.2. Financial Performance
    • 9.2.3. Product Benchmarking
    • 9.2.4. Recent Development
  • 9.3. Exactech, Inc.
    • 9.3.1. Company Overview
    • 9.3.2. Financial Performance
    • 9.3.3. Product Benchmarking
    • 9.3.4. Recent Development
  • 9.4. Globus Medical Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Financial Performance
    • 9.4.3. Product Benchmarking
    • 9.4.4. Recent Development
  • 9.5. Johnson & Johnson (DePuy Synthes)
    • 9.5.1. Company Overview
    • 9.5.2. Financial Performance
    • 9.5.3. Product Benchmarking
    • 9.5.4. Recent Development
  • 9.6. Kuros Biosciences
    • 9.6.1. Company Overview
    • 9.6.2. Financial Performance
    • 9.6.3. Product Benchmarking
    • 9.6.4. Recent Development
  • 9.7. Medtronic plc
    • 9.7.1. Company Overview
    • 9.7.2. Financial Performance
    • 9.7.3. Product Benchmarking
    • 9.7.4. Recent Development
  • 9.8. NuVasive, Inc.
    • 9.8.1. Company Overview
    • 9.8.2. Financial Performance
    • 9.8.3. Product Benchmarking
    • 9.8.4. Recent Development
  • 9.9. Organogenesis Inc.
    • 9.9.1. Company Overview
    • 9.9.2. Financial Performance
    • 9.9.3. Product Benchmarking
    • 9.9.4. Recent Development
  • 9.10. Orthofix Medical Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Financial Performance
    • 9.10.3. Product Benchmarking
    • 9.10.4. Recent Development
  • 9.11. RTI Surgical Holdings, Inc.
    • 9.11.1. Company Overview
    • 9.11.2. Financial Performance
    • 9.11.3. Product Benchmarking
    • 9.11.4. Recent Development
  • 9.12. SeaSpine Holdings Corporation
    • 9.12.1. Company Overview
    • 9.12.2. Financial Performance
    • 9.12.3. Product Benchmarking
    • 9.12.4. Recent Development
  • 9.13. Spine Wave, Inc.
    • 9.13.1. Company Overview
    • 9.13.2. Financial Performance
    • 9.13.3. Product Benchmarking
    • 9.13.4. Recent Development
  • 9.14. Stryker Corporation
    • 9.14.1. Company Overview
    • 9.14.2. Financial Performance
    • 9.14.3. Product Benchmarking
    • 9.14.4. Recent Development
  • 9.15. Zimmer Biomet Holdings, Inc.
    • 9.15.1. Company Overview
    • 9.15.2. Financial Performance
    • 9.15.3. Product Benchmarking
    • 9.15.4. Recent Development